Change in Ratings
upgraded at Goldman Sachs to Neutral from Sell. Expect organizational changes, impressive 2008 results and end to restructuring charges to provide stability to shares. Price target lowered to $4.90 from $7.60.
downgraded at Citigroup from Buy to Hold. Valuation call, based on a $37 price target.
downgraded at J.P. Morgan to Underweight from Neutral based on risks to earnings and margins. Believe sell-side estimates could be at risk based on currency effects and combination of higher inventories and decelerating sales environment. Price target cut to $16 from $19.
downgraded at Merrill from Buy to Neutral. Estimates also cut, given lower expected results in the North American economy.
downgraded at Citigroup from Hold to Sell. $8 price target. Estimates also cut, assuming a higher medical loss ratio. Stock can trade down to tangible book value. Health Net target cut at Credit Suisse to $11 from $24. Maintained Neutral rating.
upgraded at Credit Suisse to Outperform from Neutral. Cites attractive risk/reward coupled with solid defensive growth. Maintained $34 target price.
downgraded at Merrill to Neutral. $36 price target. Company may have to raise more capital if the market pulls back from current levels.
downgraded at Goldman Sachs to Sell from Neutral due to slowdown in core growth and impact from increasing competition in MCUs. Note increasing pace of customer upgrades away from 8-bit to 16- and 32-bit. Price target cut to $21 from $26.
upgraded at Merrill to Buy. Company can generate high-teens ROE in a normal environment, reducing the risk that it will have to raise a lot of capital.
downgraded at Wachovia to Underperform. Weak retail and capital markets should plague earnings in 2009. Company is also hurt by the current interest rate structure.
downgraded at Merrill to Neutral. $31 price target. Valuation call, as the stock is up 62% since earnings.
Stock Comments/EPS Changes
numbers cut at Morgan Stanley. Shares now seen reaching $26. Estimates also lowered to match the company's new guidance. Equal-weight rating.
price target raised at Goldman to $93 from $90 following strong Q3 earnings results. Maintained Buy rating.
numbers cut at Morgan Stanley. Target lowered to $52. Estimates also cut, given the company's new guidance. Overweight rating.
target trimmed at Goldman to $54 from $56 based on lower earnings expectations related to currency volatility. Fundamentals remain extremely strong. Maintained Buy rating.
price target lowered at Goldman to $21 from $23. Company lowered Cessna 2009 production expectations. Maintained Neutral rating.
This article was written by a staff member of TheStreet.com.